BRPI1013766A2 - "derivados de isoxazol-piridina como moduladores de gaba" - Google Patents

"derivados de isoxazol-piridina como moduladores de gaba"

Info

Publication number
BRPI1013766A2
BRPI1013766A2 BRPI1013766A BRPI1013766A BRPI1013766A2 BR PI1013766 A2 BRPI1013766 A2 BR PI1013766A2 BR PI1013766 A BRPI1013766 A BR PI1013766A BR PI1013766 A BRPI1013766 A BR PI1013766A BR PI1013766 A2 BRPI1013766 A2 BR PI1013766A2
Authority
BR
Brazil
Prior art keywords
pyridine derivatives
gaba modulators
isoxazole pyridine
isoxazole
gaba
Prior art date
Application number
BRPI1013766A
Other languages
English (en)
Inventor
Andrew Thomas
Bernd Buettelmann
Henner Knust
Matthew C Lucas
Roland Jakob-Roetne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI1013766A2 publication Critical patent/BRPI1013766A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI1013766A 2009-05-07 2010-04-28 "derivados de isoxazol-piridina como moduladores de gaba" BRPI1013766A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09159631 2009-05-07
PCT/EP2010/055701 WO2010127978A1 (en) 2009-05-07 2010-04-28 Isoxazole-pyridine derivatives as gaba modulators

Publications (1)

Publication Number Publication Date
BRPI1013766A2 true BRPI1013766A2 (pt) 2016-04-05

Family

ID=42235916

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013766A BRPI1013766A2 (pt) 2009-05-07 2010-04-28 "derivados de isoxazol-piridina como moduladores de gaba"

Country Status (13)

Country Link
US (1) US8357703B2 (pt)
EP (1) EP2427457B1 (pt)
JP (1) JP5481555B2 (pt)
KR (1) KR101354416B1 (pt)
CN (1) CN102414203B (pt)
AU (1) AU2010244555A1 (pt)
BR (1) BRPI1013766A2 (pt)
CA (1) CA2757412C (pt)
ES (1) ES2430223T3 (pt)
IL (1) IL215169A0 (pt)
MX (1) MX2011011484A (pt)
SG (1) SG175318A1 (pt)
WO (1) WO2010127978A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
US8227461B2 (en) * 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
RU2012116124A (ru) * 2009-09-21 2013-10-27 Вандербилт Юниверсити О-БЕНЗИЛ НИКОТИНАМИДНЫЕ АНАЛОГИ КАК ПОЗИТИВНЫЕ АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ mGluR5
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
MX341471B (es) 2010-11-05 2016-08-22 Hoffmann La Roche Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
EP2457569A1 (en) * 2010-11-05 2012-05-30 F. Hoffmann-La Roche AG Use of active pharmaceutical compounds for the treatment of central nervous system conditions
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2876778A1 (en) 2012-06-26 2014-01-03 Saniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP4126858B1 (en) 2020-03-26 2026-03-18 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
US20240425491A1 (en) 2021-05-05 2024-12-26 University College Cardiff Consultants Limited Heteroaryl compounds useful in the treatment of cognitive disorders
WO2025042940A1 (en) * 2023-08-21 2025-02-27 Cz Biohub Sf, Llc Compounds as gaba receptor modulators

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3525205A1 (de) 1984-09-11 1986-03-20 Hoechst Ag, 6230 Frankfurt Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols
GB9808663D0 (en) 1998-04-23 1998-06-24 Merck Sharp & Dohme Therapeutic agents
US6660753B2 (en) * 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
IT1314191B1 (it) 1999-10-18 2002-12-06 Recordati Chem Pharm Derivati isossazolcarbossamidici
CA2388593A1 (en) 1999-11-12 2001-05-17 Neurogen Corporation Bicyclic and tricyclic heteroaromatic compounds
PY0119496A (es) * 2000-08-07 2003-11-03 Neurogen Corp Compuestos heterociclicos como ligandos de receptores gabaa
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
GB0108475D0 (en) 2001-04-04 2001-05-23 Merck Sharp & Dohme New compounds
CA2454613A1 (en) 2001-07-05 2003-01-16 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as mch selective antagonists
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
WO2003044017A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company Beta 3 adrenergic agonists
GB0128160D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Novel compounds
JP2006515838A (ja) 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
JP2008502687A (ja) 2004-06-14 2008-01-31 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
ATE415385T1 (de) 2004-10-01 2008-12-15 Hoffmann La Roche Hexafluorisopropanolsubstituierte etherderivate
WO2006044617A1 (en) 2004-10-15 2006-04-27 The Scripps Research Institute Oxadiazole ketone inhibitors of fatty acid amide hydrolase
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2007009275A1 (de) 2005-07-20 2007-01-25 Prospective Concepts Ag Pneumatische kissenstrukturen
EP1931661B1 (en) 2005-09-19 2008-11-19 F.Hoffmann-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
JP5081161B2 (ja) 2005-12-19 2012-11-21 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
CA2640476A1 (en) 2006-02-03 2007-08-16 Eli Lilly And Company Compounds and methods for modulating fx-receptors
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
MX2008014796A (es) * 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
UA100132C2 (en) * 2007-12-04 2012-11-26 Ф. Хоффманн-Ля Рош Аг Isoxazolo-pyridine derivatives

Also Published As

Publication number Publication date
WO2010127978A1 (en) 2010-11-11
JP5481555B2 (ja) 2014-04-23
AU2010244555A1 (en) 2011-11-03
SG175318A1 (en) 2011-11-28
MX2011011484A (es) 2011-11-18
EP2427457B1 (en) 2013-07-17
EP2427457A1 (en) 2012-03-14
ES2430223T3 (es) 2013-11-19
US20100286117A1 (en) 2010-11-11
IL215169A0 (en) 2011-12-29
JP2012526072A (ja) 2012-10-25
CA2757412A1 (en) 2010-11-11
KR20120013408A (ko) 2012-02-14
KR101354416B1 (ko) 2014-02-19
US8357703B2 (en) 2013-01-22
CN102414203A (zh) 2012-04-11
CN102414203B (zh) 2014-11-26
CA2757412C (en) 2016-04-05

Similar Documents

Publication Publication Date Title
BRPI1013766A2 (pt) "derivados de isoxazol-piridina como moduladores de gaba"
BRPI1014636A2 (pt) moduladores de gpr 119
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
EP2404918A4 (en) pyridine
EP2511268A4 (en) oxazine
BRPI1008939A2 (pt) 2-mercaptoquinolina-3-carboxamidas substituídas como moduladores de kncq2/3.
CU24152B1 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
BRPI1012770A2 (pt) derivados de tiofeno
EP2462134A4 (en) N1-sulfonyl-5-FLUORPYRIMIDINON DERIVATIVES
BR112012000763A2 (pt) derivados de piridin-4-ila
PT2528897E (pt) Derivados de piridina dissubstituída como anticancerígenos
BR112012015868A2 (pt) derivados de imidazolidinadiona
EP2433940A4 (en) SPIROIMIDAZOLONDERIVAT
BRPI1013844A2 (pt) derivados de piridina-isoxazol
BRPI0809930A2 (pt) Derivados de carboxamida imidazolidina como moduladores de p2x7
BRPI0915064A2 (pt) derivados de qunoxalinadiona
EP2397480A4 (en) DIAZEPINEDIONEDERIVATE
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
CU23870B1 (es) Derivados de ciclopropilamida como moduladores h3
DK2435410T3 (da) LXR-modulatorer
BRPI0822058A2 (pt) Derivados de 5-oxo-3-pirrolidinacarboxamida como moduladores de p2x7
BRPI1014454A2 (pt) derivados de isoxazol-pirazol
BRPI1009428A2 (pt) 3-aminoisoxazolopiridina substituída como moduladores de kcnq2/3
BR112012005503A2 (pt) derivados de isoxazolidina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2512 DE 26-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.